Back to search results

Galvokimig for Atopic Dermatitis

This study is testing a drug called galvokimig to see how well it works and how safe it is for adults with moderate-to-severe atopic dermatitis (eczema). Researchers want to find the best dose of galvokimig. You might receive galvokimig or a placebo (an inactive substance that looks like the study drug). To join, you must be at least 18 years old and have had chronic atopic dermatitis for at least one year. The main goal is to see if your eczema improves significantly (at least 75% reduction in Eczema Area and Severity Index, or EASI) after 16 weeks. The current recruitment status is unclear, and the study plans to enroll about 160 participants.

Study design
This is an interventional study comparing different doses of galvokimig to a placebo. It plans to enroll about 160 adult participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 16, indicating follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07277660

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Recruiting
PHASE2Ages 18+InterventionalTreatment
UCB Biopharma SRL
~160 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:GalvokimigPlacebo

At a glance

Recruiting sites
10 of 68 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants with Eczema Area and Severity Index (EASI)75 response at Week 16
Measured over Week 16

Conditions

Atopic Dermatitis

Explore related trials

Atopic Dermatitis

Where it's being run

68 sites across 19 states
Poland13
Bulgaria7
Japan7
Germany6
Czechia5
Texas4
Canada4
United Kingdom4

Study leadership

  • UCB Cares · STUDY_DIRECTOR · 001 844 599 22733

Who to contact

UCB Cares
[email protected]
+18445992273
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant must be aged greater than or equal (≥)18 years at the time of signing the informed consent
Participant has chronic atopic dermatitis (AtD) (according to American Academy of Dermatology Consensus Criteria) that has been present for at least ≥1 year prior to initiating the study (ie, signing of the informed consent form \[ICF\]) and with:

Exclusion

Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the study participant's ability to participate in this study
Active dermatologic conditions that may confound the diagnosis of AtD or would interfere with assessment of treatment, such as but not limited to scabies, seborrheic dermatitis, cutaneous lymphoma, ichthyosis, psoriasis, active allergic or irritant contact dermatitis
Presence or family history (first degree) of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
History of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months prior to the Baseline (including herpes zoster) as judged by the investigator
Previous treatment with galvokimig
Participant has relevant safety events to one or more interleukin (IL)-13 biologic response modifiers (ie, dupilumab, tralokinumab and lebrikizumab) that resulted in discontinuation and change of treatment
All systemic therapies (other than biologics), topical therapies and other treatments for AtD must be discontinued at least 4 weeks prior to Baseline
Treatment with biologic agents must discontinued at least 3 months prior to baseline

What this trial measures

  • Percentage of participants with Eczema Area and Severity Index (EASI)75 response at Week 16Week 16

    The EASI is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. The severity of each clinical sign is scored as: 0=None to 3=Severe.